Datamonitor Healthcare's mid pharma peer set, a group that boasts efficiency in R&D but still relies on business development for growth, has signed a significant number of alliances over the past six years to build out the pipeline in innovative areas.
A secondary offering by the privately held antibody discovery play has valued the company at more than a billion dollars and allowed its venture investors to cash in some or all of their positions. Meanwhile, Adimab continues to announce new partnerships including a monoclonal and bispecific antibody discovery pact with Sanofi.
Reskinning is a polarizing force in the mobile gaming industry. Some argue it's a get-rich-quick scheme, while others insist that it's a viable business model to efficiently get mobile games into the app store. But the truth is, reskinning can be both, depending on a dev's approach.